Unusual variants of endometrial endometrioid adenocarcinoma can be diagnostically challenging and pose difficulties to differentiate from their benign and malignant mimickers. Here we describe an entity that has been well documented in the literature, yet little is known about true outcome due to lack of studies with a large number of cases. Diffusely infiltrative or "adenoma-malignum-like" is an uncommon pattern of invasion in endometrioid endometrial adenocarcinoma which could be confused with adenomyosis. To the best of our knowledge only 58 cases (excluding these 2 cases) have been reported up to date in the English literature.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association of stromal tumor-infiltrating lymphocytes with clinicopathological parameters in endometrial cancer.
Korean J Clin Oncol
December 2024
Department of Pathology, Safdarjung Hospital, Vardhman Mahavir Medical College, New Delhi, India.
Purpose: Endometrial cancer (EC) ranks as one of the most prevalent gynecological malignancies globally. The presence and role of stromal tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment have garnered interest due to their prognostic and therapeutic potential. This study aimed to evaluate the association between stromal TILs and various clinicopathological parameters in EC.
View Article and Find Full Text PDFHER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions.
Medicina (Kaunas)
December 2024
5th Department of Oncology, Metropolitan General Hospital, 155 62 Athens, Greece.
The most common histological subtypes of endometrial cancer consist of endometrioid and uterine serous carcinoma, with the latter being more aggressive and accompanied by poor prognosis. Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor associated with cell proliferation, differentiation, and survival. HER2 positivity can be diagnosed in many solid tumors.
View Article and Find Full Text PDFRelation of squamous differentiation in endometrioid carcinoma with MELF pattern to a high ratio of lymph node metastasis.
Pathol Res Pract
December 2024
Department of Pathology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. Electronic address:
One of the known histological patterns of endometrioid carcinoma (EC) in uterine corpus cancer is MELF (microcystic, elongated, and fragmented). MELF is associated with lymphovascular invasion and lymph node metastasis. Besides MELF, it is also known that squamous differentiation (SD) often occurs in EC.
View Article and Find Full Text PDFLow-grade endometrial endometrioid carcinoma of the p53-abnormal group: case presentation and diagnostic issues.
Pathologica
October 2024
Pathology Unit, Department of Oncology, ASST Sette Laghi, Varese, Italy.
P53-abnormal endometrial carcinomas are high-grade and aggressive tumors which should be treated with chemo-/radiotherapy. In low-grade endometrioid carcinoma (LGEC), abnormal expression of p53 is an exceptional finding and is typically accompanied by patchy p16 positivity and diffuse hormone receptor expression. Herein, we report a case of LGEC exhibiting both p53 and p16 overexpression, highlighting the diagnostic pitfalls related to such phenotype.
View Article and Find Full Text PDFNCAPG promotes the malignant progression of endometrioid cancer through LEF1/SEMA7A/PI3K-AKT.
J Cancer
January 2025
Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Article Synopsis
- NCAPG contributes to the development of endometrial cancer by activating the PI3K-AKT signaling pathway, making it a potential tumor marker.
- The study utilized advanced techniques like ATAC-Seq, CHIP, and CoIP to demonstrate how NCAPG influences cell proliferation and invasion by modulating LEF1's interaction with chromatin, which subsequently affects the transcription of SEMA7A.
- The NCAPG/LEF1/SEMA7A pathway is linked to cancer progression and severity in patients, suggesting that targeting this molecular pathway could lead to new treatments for endometrial cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!